Drug Trial Radar · NCT01839175
Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
Last checked: Nov 20, 2026Latest source record: Sep 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Apr 2013
Primary completion
Jul 2014
Study completion Feb 2015
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 46 days, up to 76 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Series Primary objectives * To demonstrate that the concomitant administration of the hexavalent vaccine with a meningococcal serogroup C conjugate vaccine is non inferior to the administration of the hexavalent vaccine without a MenC vaccine concomitantly in term of seroprotection rate for hepatitis B one month after the third dose of the hexavalent vaccine * To demonstrate that the concomitant administration of a MenC vaccine with the hexavalent vaccine induces an acceptable response for MenC in term of seroprotection rate (SPR) one month after the second dose of MenC Booster Primary objectives \- To describe the immunogenicity of a booster dose of the hexavalent vaccine and of a meningococcal group ACWY conjugate (MenACWY) vaccine either co-administered at 12 months of age or given separately.
Conditions
- Neisseria Meningitidis
- Bacterial Infections
- Virus Diseases
Interventions
Hexavalent vaccineBiological
0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
NeisVac-CBiological
0.5 mL intramuscular injection at 2 and 4 months of age
Prevenar 13Biological
0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
RotaTeqBiological
2 mL oral administration at 2, 3 and 4 months
NimenrixBiological
0.5 mL intramuscular injection at 12 months
M-M-RVAXPROBiological
0.5 mL intramuscular or subcutaneous injection at 13 months of age
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with an anti-hepatitis B concentration ≥10 IU/mLTime frame: Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)
- Proportion of subjects with an anti-MenC titre ≥1:8 dilTime frame: Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Sanofi Pasteur MSD Investigational Site 003
Espoo, Finland
Sanofi Pasteur MSD Investigational Site 001
Helsinki, Finland
Sanofi Pasteur MSD Investigational Site 002
Helsinki, Finland
Sanofi Pasteur MSD Investigational Site 011
Jarvenpaa, Finland
Sanofi Pasteur MSD Investigational Site 010
Kokkola, Finland
Sanofi Pasteur MSD Investigational Site 004
Oulu, Finland
Sanofi Pasteur MSD Investigational Site 005
Pori, Finland
Sanofi Pasteur MSD Investigational Site 009
Seinäjoki, Finland
Sanofi Pasteur MSD Investigational Site 006
Tampere, Finland
Sanofi Pasteur MSD Investigational Site 007
Turku, Finland
Sanofi Pasteur MSD Investigational Site 008
Vantaa, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.